



Therapeutic Drugs Targeting DNA

Guest Editors:

Prof. Dr. Mitsuko Masutani

Department of Molecular and
Genomic Biomedicine, Nagasaki
University Graduate School of
Biomedical Sciences, Nagasaki
852-8523, Japan
Center for Bioinformatics and
Molecular Medicine, Nagasaki
University Graduate School of
Biomedical Sciences, Nagasaki
852-8523, Japan

Dr. Tadayoshi Bessho

The Eppley Institute for Research
in Cancer and Allied Diseases,
Fred & Pamela Buffett Cancer
Center, University of Nebraska
Medical Center, Omaha, NE
68198-6805, USA

Deadline for manuscript
submissions:
closed (31 January 2022)

Message from the Guest Editors

Dear Colleagues,

DNA-targeting drugs that directly interact with DNA, such as alkylating, crosslinking, and DNA intercalating agents have been used in cancer chemotherapies for decades with some success. Recently, drugs that selectively target DNA repair factors have been developed, with some of these drugs currently under clinical trial. DNA repair inhibitors with a selective target, such as inhibitors of poly(ADP-ribose) polymerase, indirectly introduce lethal DNA damage to cancer cells. Inhibitors of epigenetic and chromatin regulation also indirectly target DNA, causing cancer cell death. DNA targeting drugs that induce lethal DNA damage directly or indirectly will become a critical component of effective cancer chemotherapies in the future. Thus, this Special Issue will focus on the use of DNA targeting drugs, namely those that target DNA repair and epigenetic and chromatin regulation, for various diseases, including cancers. Authors are invited to submit original research articles and reviews on various types of molecular and biological aspects of DNA targeting drugs for inclusion in this Special Issue.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Maurizio Battino

Department of
Odontostomatologic and
Specialized Clinical Sciences,
Sez-Biochimica, Faculty of
Medicine, Università Politecnica
delle Marche, Via Ranieri 65,
60100 Ancona, Italy

Message from the Editor-in-Chief

The International Journal of Molecular Sciences (*IJMS*, ISSN 1422-0067) is an open access journal, which was established in 2000. The journal aims to provide a forum for scholarly research on a range of topics, including biochemistry, molecular and cell biology, molecular biophysics, molecular medicine, and all aspects of molecular research in chemistry. *IJMS* publishes both original research and review articles, and regularly publishes special issues to highlight advances at the cutting edge of research. We invite you to read recent articles published in *IJMS* and consider publishing your next paper with us.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, MEDLINE, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Biochemistry & Molecular Biology*) / CiteScore - Q1 (*Inorganic Chemistry*)

Contact Us

*International Journal of Molecular
Sciences* Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/ijms
ijms@mdpi.com
X@IJMS_MDPI